Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Li, JingWei, Woodward, Mark, Perkovic, Vlado, Figtree, Gemma A., Heerspink, Hiddo J.L., Mahaffey, Kenneth W., de Zeeuw, Dick, Vercruysse, Frank +3 more·2020·JACC: Heart Failure
DOI 10.1016/j.jchf.2019.08.004

Cited by (144)

Items 101–144 of 144

  1. Macrovascular Risk Equations Based on the CANVAS Program
    Michael S. Willis, Christian Asseburg, April E Slee, Andreas Nilsson, Cheryl A. Neslusan · 2021 · PharmacoEconomics
  2. Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes
    Bernhard Karl Krämer, Sibylle Jenny Hauske, ROBERT J. CHILTON, Johannes F.E. Mann, Lars Lysgaard Gullestad, DAVID H. FITCHETT, Michaela Mattheus, Dominik Steubl, Christoph Wanner · 2023 · Journal of Diabetes and its Complications
  3. Limitations of Natriuretic Peptide Levels in Establishing SGLT-2 Inhibitors for Heart Failure Care
    Eric J. Velazquez, Samuel W. Reinhardt · 2020 · Journal of the American College of Cardiology
  4. Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure
    Yuliya Lytvyn, Rosalie Annemien Scholtes, Eva M. Boorsma, Vikas S. Sridhar, Luxcia Kugathasan, Hongyan Liu, Leif Erik Lovblom, M. Louis Handoko, Charlotte M. Mosterd, John S. Floras et al. · 2025 · Physiological Reports
  5. Heterogeneous cardiovascular effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a causal forest and target trial emulation study
    Yuichiro Mori, Toshiaki Komura, Motohiko Adomi, Ryuichiro Yagi, Shingo Fukuma, Koji Kawakami, Naoki Kondo, Yusuke Tsugawa, Daisuke Yabe, Motoko Yanagita et al. · 2025 · European Journal of Preventive Cardiology
  6. Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
    Veera Ganesh Yerra, Kim Alexander Connelly · 2024 · Physiology
  7. Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice
    Helen Goodluck, Alice E. Zemljic‐Harpf, Ony Araújo Galdino, Sadhana Kanoo, Natalia Lopez, Young‐Chul Kim, Volker Vallon · 2025 · Physiological Reports
  8. SGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective
    Panagiotis Theofilis, Rigas Kalaitzidis · 2022 · Current Medicinal Chemistry
  9. The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice
    Pieter Martens, Chantal Mathieu, Thomas Vanassche · 2022 · Acta cardiologica. Supplementum
  10. The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
    Luxcia Kugathasan, Lisa Dubrofsky, Andrew Advani, David Z.I. Cherney · 2022 · Expert Review of Cardiovascular Therapy
  11. De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study
    Luis Miguel Perez-Belmonte, Michele Ricci, Jaime Sanz‐Cánovas, Lidia Cobos-Palacios, Maria Dolores Lopez-Carmona, Maria Isabel Ruiz-Moreno, Mercedes Millán‐Gómez, María Rosa Bernal-López, Sergio Jansen‐Chaparro, Ricardo Gómez‐Huelgas · 2021 · Journal of Clinical Medicine
  12. Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
    Vikas S. Sridhar, Luxcia Kugathasan, Yuliya Lytvyn, Yangqing Deng, Hongyan Liu, Leif Erik Lovblom, JOSEPHINE M. TSE, Massimo Nardone, John S. Floras, Tosin Osuntokun et al. · 2025 · Hypertension
  13. Erythropoiesis and estimated fluid volume regulation following initiation of ipragliflozin treatment in patients with type 2 diabetes mellitus and chronic kidney disease: A post‐hoc analysis of the PROCEED trial
    Tatsuya Maruhashi, Atsushi Tanaka, Kanae Takahashi, Yukihito Higashi, Koichi Node, the PROCEED trial investigators · 2024 · Diabetes Obesity and Metabolism
  14. The Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Anemia in Type 2 Diabetes-A Real-World Study
    Tali Steinmetz, Shira N. Goldman, Kim Ben Tikva Kagan, Dana Bielopolski, Shira Buchrits, Amir Schechter, Shiri Kushnir, ‪Adi Turjeman‬‏, Timna Agur, Alon Grossman et al. · 2025 · The Journal of Clinical Endocrinology & Metabolism
  15. The importance of targeting multiple risk markers in patients with type 2 diabetes: A post‐hoc study from the CANVAS programme
    Sok Cin Tye, Megumi Oshima, Clare Gabrielle Arnott, Brendon Lange Neuen, Robert A. Fletcher, Bruce Charles Neal, Hiddo J.L. Heerspink · 2023 · Diabetes Obesity and Metabolism
  16. Sodium-Glucose Cotransporter-2 Inhibitors Across the Glycemic Spectrum: Cardiovascular and Renal Outcomes With Mechanistic Insights
    Raghad Abdelfadil Elgazzar, Mahmoud Mohammed Ramadan · 2026 · Cureus
  17. Physiology of Kidney Glucose Transport and Mechanisms of Kidney Protection by SGLT2 Inhibitors
    Volker Vallon · 2026 · Handbook of experimental pharmacology
  18. Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor
    Maia P. Gill, Marianna Leung, C. Luo, Catherine Cheung, Arielle Beauchesne, Doris Chang, James H. Lan, Olwyn Johnston · 2023 · Clinical Transplantation
  19. Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial
    Akihiko Koshino, Brendon Lange Neuen, Megumi Oshima, Tadashi Toyama, Akinori Hara, Clare Gabrielle Arnott, Bruce Charles Neal, Meg Jardine, Sunil V. Badve, Kenneth W. Mahaffey et al. · 2023 · Kidney International Reports
  20. Impact of Empagliflozin on the Outcomes of β-Thalassemia Major in Patients With Type 2 Diabetes Mellitus: The THALEMPA Observational Study
    Anas Ibraheem, Waseem F. Al Tameemi · 2024 · Cureus
  21. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Lipid Modulation in Heart Failure: A Narrative Review
    Sina Neshat, Hazhir Moradi, Matin Bidares, Afshin Heidari, Alireza Falahati Marvast, Ronal Ortega, Kiyan Heshmat · 2025 · Cureus
  22. Erythrocytosis after SGLT2 inhibitor initiation and anticoagulated outcomes in atrial fibrillation: a real-world analysis with counterfactual modeling
    Zuo Qi, Jiayi Liu, T S Gu, Ning Wu, Junyu Liu, Jinhua Zhao, Gary Tse, Gregory Y.H. Lip, Kang Yin Chen, Tong Liu · 2026 · Cardiovascular Diabetology
  23. Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial
    Abhinav Sharma, Pedro Sousa Marques, Brendon Lange Neuen, Robert A. Fletcher, April E Slee, Wally Rapattoni, Fernando G. Ang, Clare Gabrielle Arnott, Adeera Levin, Subodh Verma et al. · 2023 · Diabetes Obesity and Metabolism
  24. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism
    Hafiz M. Imran, William A. Nester, Islam Y. Elgendy, Marwan S Saad · 2020 · Annals of Medicine
  25. Inhibidores del SGTL-2 en pacientes con insuficiencia cardiaca y fracción de eyección reducida con o sin diabetes: revisión sistémica
    Henry Mejía-Zambrano · 2022 · Revista Peruana de Investigación en Salud
  26. Mediators of the Effects of Canagliflozin on Heart Failure
    Kevin Bryan Lo, Peter Andrew McCullough, Janani Rangaswami · 2020 · JACC Heart Failure
  27. Reply
    Hiddo J.L. Heerspink, Jingwei Li, Bruce Charles Neal, Dick de Zeeuw · 2020 · JACC Heart Failure
  28. Extending the use of SGLT2 inhibitors from diabetic to non-diabetic kidney disease
    Claire C. J. Dekkers · 2020
  29. Mediators of the effects of canagliflozin on N‐terminal pro‐brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial
    Atsushi Tanaka, Takumi Imai, Makoto Suzuki, Shinya Hiramitsu, Naohiko Takahashi, Toshiaki Kadokami, Arihiro Kiyosue, Masami Nishino, Yasushi Sakata, Koichi Node et al. · 2022 · Diabetes Obesity and Metabolism
  30. Empagliflozin as a part of optimal medical therapy for chronic heart failure
    Tatiana M. Uskach · 2022 · Russian Cardiology Bulletin
  31. Mechanisms of SGLT2 inhibition in the kidney
    Taha Sen · 2023
  32. The Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Individuals with Diabetes Mellitus Type two and Heart Failure
    Ahmed Hamza Al-Shammari, Zainab A. Abbood, Hayder F. Lateef · 2023 · International Journal of Pharmaceutical and Bio-Medical Science
  33. The Effect of SGLT2 Inhibitor on Renal Anemia in Patients with Moderate to Severe Diabetic Kidney Disease
    Chuanlei Li, Jack Kit‐Chung Ng, Gordon Chun‐Kau Chan, Winston WS Fung, Kai Ming Chow, Cheuk‐Chun Szeto · 2024 · Research Square
  34. EFFECT OF GLIFLOZINS ON RENAL DYSFUNCTION IN CHRONIC HEART FAILURE WITH ANEMIA
    A. G. Gadaev, F. I. Khujakulova · 2023 · Oriental Journal of Medicine and Pharmacology
  35. New perspectives on SGLT2 inhibitors in diabetic kidney disease: focus on hematology and inflammation
    Akihiko Koshino · 2024
  36. Additional file 1 of Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study
    Wong, Carlos King Ho, Kristy T. K. Lau, Eric Ho Man Tang, Lee, Chi Ho, Carmen Yu Yan Lee, Woo, Yu Cho, Ivan Chi Ho Au, K. C. B. Tan, David Tak Wai Lui · 2022 · Figshare
  37. Additional file 1 of Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials
    Masashi Hasebe, Satoshi Yoshiji, Yamato Keidai, Hiroto Minamino, Murakami, Takaaki, Tanaka, Daisuke, Fujita, Yoshihito, Norio Harada, Akihiro Hamasaki, Inagaki, Nobuya · 2024 · Figshare
  38. Additional file 1 of Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT)
    Tanaka, Atsushi, Imai, Takumi, Toyoda, Shigeru, Kazuhiro Sugimoto, Yoshida, Ruka, Machi Furuta, Node, Koichi · 2023 · Figshare
  39. Additional file 4 of Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
    Giulia Ferrannini, Norman R Rosenthal, Michael K. Hansen, Ferrannini, Ele · 2022 · Figshare
  40. Changes in the metabolome after treatment with canagliflozin in patients with type 2 diabetes
    Craig Peter Coorey, Owen Tang, Mengbo Li, Taiyun Kim, Joshua Vescovi, Stephen Thomas Vernon, Bruce Charles Neal, Clare Gabrielle Arnott, Ele Ferrannini, Louise M. Burrell et al. · 2026 · Heart
  41. A Study on the Effects of Finerenone on Hemoglobin, Hematocrit, and Serum Albumin Levels in Real-World Clinical Practice
    Nakai Kazuaki · 2026 · Cureus
  42. Translating Guidelines into Practice: Implementation of NT-proBNP Testing for Early Heart Failure Detection in Diabetes, a Narrative Review
    Rodica Pop‐Busui, Ana María Cebrián Cuenca, Jonas Čeponis, Andrea Da Porto, Jonathan Dos Santos, Cristina Gavina, Giacomo Gastaldi, Andrej Janež, Ameya S Joshi, Kenneth McDonald et al. · 2026 · Journal of General Internal Medicine
  43. Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin
    Evagelia E Habeos, Georgios Κ. Markantes, Anastasia Parthymou, Konstantinos Dimitropoulos, George I. Habeos, Marios Papasotiriou, Markos N. Marangos, Dionysios V. Chartoumpekis · 2026 · Biomedicines
  44. Type 2 Diabetes: Chronic Clinical Metabolic Effects of SGLT2 Inhibitors
    André Jacques Scheen · 2026 · Handbook of experimental pharmacology